Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate

Mod Rheumatol. 2014 Jul;24(4):681-4. doi: 10.3109/14397595.2013.874736. Epub 2014 Feb 18.

Abstract

A 63-year-old male Japanese rheumatoid arthritis (RA) patient, in whom treatment with infliximab and methotrexate (MTX) had once led to drug-free remission, experienced a disease flare in July 2010. He was retreated with a combination of adalimumab and MTX, and clinical remission was achieved in 3 months. In contrast, power Doppler signals by ultrasonography with increased serum vascular endothelial growth factor still remained after he achieved sustained clinical remission, whereas no radiographic progression has been found.

Keywords: Adalimumab; Angiopoietin-2; Musculoskeletal ultrasonography; Rheumatoid arthritis; Vascular endothelial growth factor.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / diagnostic imaging
  • Arthritis, Rheumatoid / drug therapy*
  • Disease Progression
  • Drug Therapy, Combination
  • Humans
  • Male
  • Methotrexate / therapeutic use*
  • Synovitis / blood
  • Synovitis / diagnostic imaging*
  • Synovitis / drug therapy
  • Treatment Outcome
  • Ultrasonography
  • Vascular Endothelial Growth Factor A / blood*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Vascular Endothelial Growth Factor A
  • Adalimumab
  • Methotrexate